The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

While medical headlines often focus on the biochemical underpinnings of disease, our body's biomechanics are equally crucial.

Additionally, high blood pressure can damage blood vessels throughout the body, leading to complications such as peripheral artery disease, vision loss, and cognitive decline. Furthermore, ...

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...

Serge Belanger’s rating is based on a clear path toward FDA approval and the subsequent launch of Yutrepia, a drug developed by Liquidia Technologies for treating pulmonary arterial hypertension (PAH) ...

Another is producing a market-leading treatment for pulmonary arterial hypertension. But their appeal isn’t tethered to the ...

Pulmonary arterial hypertension (PAH) is one of five types of pulmonary hypertension. It happens when the blood vessels in your lungs narrow and scar so much that it’s hard for blood to move ...

If you have pulmonary arterial hypertension (PAH), it’s possible to lead an active, productive life. The key is to work closely with a specialist, usually a lung doctor (pulmonologist ...

Aerovate Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, focusing on developing therapies for pulmonary arterial hypertension. The company recently announced its ...

Pulmonary hypertension (PH) is a serious condition that occurs when the blood pressure in the pulmonary arteritis is comparatively higher than usual. Pulmonary arteries are a type of blood vessel ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ...